Cargando…
Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contrac...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406375/ https://www.ncbi.nlm.nih.gov/pubmed/32801832 http://dx.doi.org/10.2147/JIR.S258839 |
_version_ | 1783567406214414336 |
---|---|
author | Lichota, Anna Gwozdzinski, Krzysztof Szewczyk, Eligia M |
author_facet | Lichota, Anna Gwozdzinski, Krzysztof Szewczyk, Eligia M |
author_sort | Lichota, Anna |
collection | PubMed |
description | Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contraceptives, previous venous thromboembolism, cancer, and bacterial infections. Sepsis increases the risk of blood clot formation 2–20 times. In this review, we discussed various mechanisms related to the role of bacteria in venous thrombosis also taking into consideration the role of the human microbiome. Many known bacteria, such as Helicobacter pylori, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli, causing infections may increase the risk of thrombotic complications through platelet activation or may lead to an inflammatory reaction involving the fibrinolytic system. Additionally, the bacteria participate in the production of factors causing or increasing the risk of cardiovascular diseases. An example can be trimethylamine N-oxide (TMAO) but also uremic toxins (indoxyl sulfate), short-chain fatty acids (SCFA) phytoestrogens, and bile acids. Finally, we presented the involvement of many bacteria in the development of venous thromboembolism and other cardiovascular diseases. |
format | Online Article Text |
id | pubmed-7406375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74063752020-08-14 Microbial Modulation of Coagulation Disorders in Venous Thromboembolism Lichota, Anna Gwozdzinski, Krzysztof Szewczyk, Eligia M J Inflamm Res Original Research Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death in the world. Important risk factors of thrombosis include bed restraint, surgery, major trauma, long journeys, inflammation, pregnancy, and oral contraceptives, previous venous thromboembolism, cancer, and bacterial infections. Sepsis increases the risk of blood clot formation 2–20 times. In this review, we discussed various mechanisms related to the role of bacteria in venous thrombosis also taking into consideration the role of the human microbiome. Many known bacteria, such as Helicobacter pylori, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli, causing infections may increase the risk of thrombotic complications through platelet activation or may lead to an inflammatory reaction involving the fibrinolytic system. Additionally, the bacteria participate in the production of factors causing or increasing the risk of cardiovascular diseases. An example can be trimethylamine N-oxide (TMAO) but also uremic toxins (indoxyl sulfate), short-chain fatty acids (SCFA) phytoestrogens, and bile acids. Finally, we presented the involvement of many bacteria in the development of venous thromboembolism and other cardiovascular diseases. Dove 2020-07-30 /pmc/articles/PMC7406375/ /pubmed/32801832 http://dx.doi.org/10.2147/JIR.S258839 Text en © 2020 Lichota et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lichota, Anna Gwozdzinski, Krzysztof Szewczyk, Eligia M Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title | Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title_full | Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title_fullStr | Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title_full_unstemmed | Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title_short | Microbial Modulation of Coagulation Disorders in Venous Thromboembolism |
title_sort | microbial modulation of coagulation disorders in venous thromboembolism |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406375/ https://www.ncbi.nlm.nih.gov/pubmed/32801832 http://dx.doi.org/10.2147/JIR.S258839 |
work_keys_str_mv | AT lichotaanna microbialmodulationofcoagulationdisordersinvenousthromboembolism AT gwozdzinskikrzysztof microbialmodulationofcoagulationdisordersinvenousthromboembolism AT szewczykeligiam microbialmodulationofcoagulationdisordersinvenousthromboembolism |